Evidence map›Paper›PMID 34298724›Full record

ArticleCancers2021

Multiplexed Plasmonic Nano-Labeling for Bioimaging of Cytological Stained Samples.

Paule Marcoux-Valiquette, Cécile Darviot, Lu Wang, Andrée-Anne Grosset, Morteza Hasanzadeh Kafshgari, Mirela Birela, Sergiy Patskovsky, Dominique Trudel, Michel Meunier

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Recent Developments in Plasmonic Alloy Nanoparticles: Synthesis, Modelling, Properties and Applications.Chemphyschem : a European journal of chemical physics and physical chemistry · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Paule Marcoux-ValiquetteDepartment of Engineering Physics, Polytechnique Montréal, Montreal, QC H3T 1J4, Canada.ORCID 0000-0001-6678-8476
Cécile DarviotDepartment of Engineering Physics, Polytechnique Montréal, Montreal, QC H3T 1J4, Canada.ORCID 0000-0003-4052-3079
Lu WangDepartment of Engineering Physics, Polytechnique Montréal, Montreal, QC H3T 1J4, Canada.
Andrée-Anne GrossetCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) et Institut du Cancer de Montréal (ICM), Montréal, QC H3T 1J4, Canada.ORCID 0000-0002-7036-9597
Morteza Hasanzadeh KafshgariDepartment of Engineering Physics, Polytechnique Montréal, Montreal, QC H3T 1J4, Canada.ORCID 0000-0001-5202-8505
Mirela BirelaCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) et Institut du Cancer de Montréal (ICM), Montréal, QC H3T 1J4, Canada.
Sergiy PatskovskyDepartment of Engineering Physics, Polytechnique Montréal, Montreal, QC H3T 1J4, Canada.ORCID 0000-0001-7175-481X
Dominique TrudelCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) et Institut du Cancer de Montréal (ICM), Montréal, QC H3T 1J4, Canada.
Michel MeunierDepartment of Engineering Physics, Polytechnique Montréal, Montreal, QC H3T 1J4, Canada.ORCID 0000-0002-2398-5602
Polytechnique Montréal · CACentre Hospitalier de l’Université de Montréal · CA

Funding

Onco-Tech Competition Fund 293742TransMedTech Institute Medical Technology Innovation Fund 0049
6 · The paper itself

Abstract

Reliable cytopathological diagnosis requires new methods and approaches for the rapid and accurate determination of all cell types. This is especially important when the number of cells is limited, such as in the cytological samples of fine-needle biopsy. Immunoplasmonic-multiplexed- labeling may be one of the emerging solutions to such problems. However, to be accepted and used by the practicing pathologists, new methods must be compatible and complementary with existing cytopathology approaches where counterstaining is central to the correct interpretation of immunolabeling. In addition, the optical detection and imaging setup for immunoplasmonic-multiplexed-labeling must be implemented on the same cytopathological microscope, not interfere with standard H&E imaging, and operate as a second easy-to-use imaging method. In this article, we present multiplex imaging of four types of nanoplasmonic markers on two types of H&E-stained cytological specimens (formalin-fixed paraffin embedded and non-embedded adherent cancer cells) using a specially designed adapter for SI dark-field microscopy. The obtained results confirm the effectiveness of the proposed optical method for quantitative and multiplex identification of various plasmonic NPs, and the possibility of using immunoplasmonic-multiplexed-labeling for cytopathological diagnostics.

Indexed as

bioimagingcytopathological cancer diagnosisgold nanoparticlesgold-silver alloy nanoparticlesimmunoplasmonic-multiplexed-labelingparaffin-embedded cytological tissuesplasmonic biomarkersside-illumination microscopy

Identifiers

PMID34298724
PMCPMC8307244
OpenAlexW3180886807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.